Moxifloxacin Hikma

Moxifloxacin, the active ingredient in Moxifloxacin Hikma, is a fluoroquinolone antibiotic presented as a intravenous solution for intravenous use. It treats bacterial infections in adult patients.\nGNH India supplies Moxifloxacin Hikma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Moxifloxacin Hikma is a broad‑spectrum fluoroquinolone used to treat serious bacterial infections.\n\nCommunity‑Acquired Bacterial Pneumonia: rapid bacterial eradication and clinical recovery.\nComplicated Skin and Skin Structure Infections: effective against Gram‑positive and Gram‑negative pathogens.\nIntra‑Abdominal Infections: covers mixed aerobic and anaerobic organisms.\nAcute Bacterial Sinusitis: resolves infection and relieves symptoms.\nAcute Exacerbations of COPD: reduces bacterial load and improves lung function.

Moxifloxacin Hikma may cause a range of adverse reactions.\n\nCommon Side Effects:\n- Nausea: mild to moderate gastrointestinal upset.\n- Diarrhea: loose stools, sometimes watery.\n- Headache: transient cranial discomfort.\n- Dizziness: sensation of light‑headedness.\n- Rash: mild skin erythema or pruritus.\n- Elevated liver enzymes: transient increase in hepatic transaminases.\n\nSerious or Rare Side Effects:\n- Tendon rupture: especially Achilles tendon, may occur without warning.\n- QT interval prolongation: risk of ventricular arrhythmias.\n- Clostridioides difficile infection: severe colitis after antibiotic exposure.\n- Severe allergic reactions: anaphylaxis, angioedema.\n- Stevens‑Johnson syndrome/toxic epidermal necrolysis: life‑threatening skin reactions.\n- Hepatic failure: rare but potentially fatal liver injury.

Before using Moxifloxacin Hikma, consider the following precautions.\n\nRenal impairment: adjust therapy based on renal function and monitor for accumulation.\nHistory of tendon disorders: avoid use in patients with prior tendon injury or tendon‑rupture risk.\nQT prolongation risk: obtain baseline ECG and avoid in patients with known prolonged QT interval.\nConcurrent use with antacids or multivitamins containing magnesium or aluminum: separate administration by at least 2 hours.\nPregnancy and lactation: use only if potential benefit justifies potential risk to the fetus or infant.\nStore at ambient temperature: keep in original container, protect from light and moisture.

Moxifloxacin Hikma can interact with several medicines.\n\nMajor Interactions (Avoid):\n- Co‑administration with other fluoroquinolones: increased risk of toxicity.\n- Concurrent use with QT‑prolonging agents (e.g., macrolides, antiarrhythmics): heightened arrhythmia risk.\n- Antacids containing aluminum or magnesium: markedly reduces moxifloxacin absorption.\n- Corticosteroids: elevated risk of tendon rupture.\n\nModerate Interactions (Monitor Closely):\n- Warfarin: may enhance anticoagulant effect, monitor INR.\n- Theophylline: plasma levels may rise, watch for toxicity signs.